Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Aclidinium/Formoterol in Chinese COPD Patients
NCT03276078Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aclidinium and formoterol in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Primary endpoints: Maximum Plasma Concentration at Day 5, Time to Maximum Plasma Concentration at Day 5 and 5 more. Started Nov 2017; status: completed.
02
Drugs
aclidiniumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03276078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03276078.